Andere Sprachen Beam Therapeutics Inc.

Aktien

A2PY7P

US07373V1052

BEAM

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.04.2026			% 5 Tage	Veränd. 1. Jan.
31,39 ^USD	+3,49 %		+19,22 %	+13,24 %

02.04.	Beam Therapeutics: Insider-Verkauf im Wert von 1.128.315 Dollar laut SEC-Meldung	MT
01.04.	Beam Therapeutics veröffentlicht Daten der Phase 1/2-Studie BEACON für Risto-Cel bei Patienten mit Sichelzellkrankheit	CI

Andere Sprachen

02.04.	Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing
01.04.	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
01.04.	Beam Therapeutics Publishes Beacon Phase 1/2 Data for Risto-Cel in Patients with Sickle Cell Disease
25.03.	Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection
25.03.	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency
25.03.	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
05.03.	Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd
24.02.	Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings
24.02.	Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
24.02.	Beam Therapeutics Inc. announced that it expects to receive $500 million in funding
24.02.	Kyverna Therapeutics, Inc. Announces Board and Committee Changes
24.02.	Beam Therapeutics Inc. Announces $500 Million Strategic Financing Facility with Sixth Street
24.02.	Beam Therapeutics Secures Up to $500 Million Sixth Street Financing
24.02.	Beam Therapeutics Swings to Q4 Adjusted Earnings, Revenue Rises -- Shares Up Pre-Bell
24.02.	Beam Therapeutics announces $500 million strategic financing facility with Sixth Street
24.02.	Earnings Flash (BEAM) Beam Therapeutics Posts Q4 EPS $2.33, vs. FactSet Est of $1.01 Loss
24.02.	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q4 Revenue $114.1M, vs. FactSet Est of $11.7M
24.02.	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
24.02.	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
24.02.	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
23.02.	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
05.02.	Beam Therapeutics Inc. Announces Resignation of Carole Ho from the Board of Directors, Effective February 27, 2026
12.01.	Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise
11.01.	Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises
11.01.	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition